Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jesse Hatgis

Interventional Pain Medicine Tamarac, FL Doctor of Osteopathy

NPI 1154666139 CMS profile 510188

7171 N University Dr Ste 300, Tamarac, FL 33321

Open in the dashboard

General payments

$90,079

1,026 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$30,797 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Jesse Hatgis of Tamarac, FL is reported in the CMS Open Payments database as having received $90,079 across 1,026 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $30,797 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,279 308
2024 General $43,184 264
2023 General $4,205 138
2022 General $2,139 64
2021 General $1,158 61
2020 General $1,889 85
2019 General $2,224 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Hatgis
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jesse Hatgis were reported at $35,279. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jesse Hatgis Interventional Pain Medicine median Middle half National median
2019 $2,224 $684 $216–$2,079 $163
2020 $1,889 $382 $122–$1,109 $114
2021 $1,158 $552 $167–$1,554 $132
2022 $2,139 $605 $187–$1,924 $149
2023 $4,205 $671 $195–$1,915 $160
2024 $43,184 $684 $206–$1,837 $164
2025 $35,279 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BIOTRONIK NRO, Inc. $42,742 466 payments
  2. elliquence, LLC $28,889 19 payments
  3. Abbott Laboratories $5,865 277 payments
  4. SPR Therapeutics, Inc $4,238 36 payments
  5. Zavation LLC $1,516 6 payments
  6. Nevro Corp. $1,239 39 payments
  7. Medtronic, Inc. $870 20 payments
  8. Collegium Pharmaceutical, Inc. $712 45 payments
  9. Boston Scientific Corporation $709 30 payments
  10. Pacira Pharmaceuticals Incorporated $591 2 payments
  11. Other $2,706 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $39,689 980 payments
  2. Consulting Fee $32,150 15 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $13,131 4 payments
  4. Travel and Lodging $4,465 22 payments
  5. Honoraria $591 2 payments
  6. Education $52 3 payments
Products named General payments · program years 2019–2025
  1. Disc-FX System $28,191 11 payments
  2. Prospera Not Applicable $21,700 274 payments
  3. Prospera Not Applicable $20,231 175 payments
  4. SPRINT PNS System $4,238 36 payments
  5. Proclaim Family of SCS IPGs $2,406 142 payments
  6. PROCLAIM $2,159 87 payments
  7. INTELLIS ADAPTIVESTIM $857 19 payments
  8. BIOTRONIK $796 16 payments
  9. XTAMPZA $712 45 payments
  10. Neuromodulation-Research Only $613 5 payments
  11. Other $5,637 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,487

Median for Pain Management: 951

Drug cost

$98,967

Median for Pain Management: $26,034

Branded share of claims

56.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 860 $25,588
Belbuca Buprenorphine Hcl Brand 25 $17,132
Oxycontin Oxycodone Hcl Brand 18 $14,514
Xtampza Er Oxycodone Myristate Brand 23 $9,182
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 398 $8,035
Buprenorphine Generic 46 $7,731
Oxycodone Hcl Generic 284 $4,844
Pregabalin Generic 165 $2,473
Morphine Sulfate Er Morphine Sulfate Brand 82 $2,016
Morphine Sulfate Generic 58 $1,903

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$126,113

Of which drugs: $24

Medicare patients

127

Average age 74

Services billed

843

75 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Ischemic heart disease 39%
Chronic kidney disease 33%
Depression 33%
Osteoporosis 26%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 42 192 $17
Injection, midazolam hydrochloride, per 1 mg J2250 Office 12 36 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
$304 23 —
BOTOX
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,026 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record